Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | geminin | 0.0171 | 0.0826 | 0.0651 |
Loa Loa (eye worm) | hypothetical protein | 0.0275 | 0.2224 | 0.2243 |
Brugia malayi | NNMT/PNMT/TEMT family protein | 0.0275 | 0.2224 | 0.2243 |
Trichomonas vaginalis | alpha-L-fucosidase, putative | 0.0228 | 0.1589 | 1 |
Echinococcus granulosus | geminin | 0.0171 | 0.0826 | 0.0651 |
Trypanosoma brucei | glucosidase, putative | 0.0123 | 0.0187 | 0.5 |
Toxoplasma gondii | glycosyl hydrolase, family 31 protein | 0.0123 | 0.0187 | 0.5 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0121 | 0.0161 | 1 |
Brugia malayi | hypothetical protein | 0.0151 | 0.0563 | 0.0413 |
Loa Loa (eye worm) | glycosyl hydrolase family 31 protein | 0.0804 | 0.9269 | 1 |
Brugia malayi | Alpha-L-fucosidase family protein | 0.0519 | 0.5474 | 0.5821 |
Onchocerca volvulus | 0.0214 | 0.1407 | 0.1237 | |
Schistosoma mansoni | alpha-glucosidase | 0.0776 | 0.8897 | 1 |
Trichomonas vaginalis | alpha-L-fucosidase, putative | 0.0228 | 0.1589 | 1 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0121 | 0.0161 | 1 |
Onchocerca volvulus | 0.0663 | 0.7388 | 1 | |
Schistosoma mansoni | hypothetical protein | 0.0171 | 0.0826 | 0.0734 |
Schistosoma mansoni | hypothetical protein | 0.0171 | 0.0826 | 0.0734 |
Loa Loa (eye worm) | hypothetical protein | 0.0275 | 0.2224 | 0.2243 |
Echinococcus granulosus | lysosomal alpha glucosidase | 0.0804 | 0.9269 | 0.9255 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0121 | 0.0161 | 1 |
Mycobacterium ulcerans | alpha-L-fucosidase | 0.0859 | 1 | 0.5 |
Echinococcus multilocularis | lysosomal alpha glucosidase | 0.0804 | 0.9269 | 0.9255 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0123 | 0.0187 | 0.5 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0188 | 0.1061 | 0.0962 |
Echinococcus multilocularis | fucosidase, alpha L 1, tissue | 0.0859 | 1 | 1 |
Entamoeba histolytica | glycosyl hydrolase, family 31 protein | 0.0123 | 0.0187 | 0.5 |
Trichomonas vaginalis | set domain proteins, putative | 0.0214 | 0.1407 | 0.8701 |
Schistosoma mansoni | alpha-l-fucosidase | 0.0519 | 0.5474 | 0.607 |
Brugia malayi | Glycosyl hydrolases family 31 protein | 0.0804 | 0.9269 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0151 | 0.0563 | 0.0413 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0123 | 0.0187 | 0.5 |
Leishmania major | alpha glucosidase II subunit, putative | 0.0123 | 0.0187 | 0.5 |
Echinococcus multilocularis | lysosomal alpha glucosidase | 0.0804 | 0.9269 | 0.9255 |
Brugia malayi | Pre-SET motif family protein | 0.0188 | 0.1061 | 0.0962 |
Schistosoma mansoni | alpha-glucosidase | 0.0776 | 0.8897 | 1 |
Loa Loa (eye worm) | alpha-L-fucosidase | 0.0519 | 0.5474 | 0.5821 |
Entamoeba histolytica | glycosyl hydrolase, family 31 protein | 0.0123 | 0.0187 | 0.5 |
Loa Loa (eye worm) | NNMT/PNMT/TEMT family protein | 0.0275 | 0.2224 | 0.2243 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0121 | 0.0161 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MED (functional) | = 300 mg kg-1 | Anticonvulsant activity in ip dosed mouse assessed as inhibition of maximum electric shock-induced hind limb tonic extension after 0.5 hrs | ChEMBL. | 20947222 |
MED (functional) | = 300 mg kg-1 | Anticonvulsant activity in ip dosed mouse assessed as inhibition of PTZ-induced clonic seizure after 0.5 hrs | ChEMBL. | 20947222 |
MED (ADMET) | = 300 mg kg-1 | Neurotoxicity against ip dosed mouse by rotarod test after 0.5 hrs | ChEMBL. | 20947222 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.